Nightingale’s blood test well-received in public healthcare

Photo credit Coronaria

Nightingale’s clinical service (the extended lipid panel test) received an enthusiastic reception in public healthcare last month, where it was taken into use for the very first time in Posio (Northern Finland). As a part of Finnish health service provider Coronaria’s well-being campaign, “Posio Moves,” participants were given the opportunity to receive Nightingale’s blood testing service. Over 500 people signed up for testing, accounting for over 15 per cent of the municipality’s population. 

With a single sample, Nightingale’s extended lipid panel test measures more biomarkers than traditional cholesterol tests, allowing for better prediction of cardiovascular diseases. In addition to the same measures obtained from conventional cholesterol tests (e.g. blood glucose, cholesterol and triglyceride levels), Nightingale’s test also measures apolipoproteins B and A1 levels and their ratio. Growing evidence from public health research now supports measuring both apolipoproteins and cholesterol measurements, as it is thought they can significantly improve cardiovascular risk assessment. You can read more about this research here

Nightingale is delighted to be a part of Coronaria’s Posio Moves campaign, offering a variety of activities to people of all ages in Posio that focuses on improving their health, exercise routine and well-being. A popular kick-off event took place on April 11th, with the campaign scheduled to end on November 9th, 2018. A planned follow-up test will coincide with the end of the campaign for all participants that received blood testing at the start.